NCT00512083CompletedPhase 2
An Open Label Randomized Controlled Dose Escalating Phase II Study of AS1411 Combined With Cytarabine in the Treatment of Patients With Primary Refractory or Relapsed Acute Myeloid Leukemia
Antisoma Research19 sites in 2 countries70 target enrollmentStarted: July 1, 2007Last updated:
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Enrollment
- 70
- Locations
- 19
- Primary Endpoint
- The prorportion of patients achieving a completel response (CR) after the first cycle of treatment in each treatment group
Study Overview
Brief Summary
The overall aim of this study is to assess the efficacy and safety of AS1411, over a range of doses, when combined with cytarabine, in the treatment of patients with primary refractory or relapsed acute myeloid leukemia (AML).
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •primary refractory or relapsed AML
- •confirmed diagnosis of AML (de novo or secondary) as defined by WHO classification (Vardiman 2002)
- •aged at least 18 years
Exclusion Criteria
- •initial diagnosis of acute promyelocytic leukemia as defined by French-American-British criteria (Bennett 1976)
- •patient in blast crisis stage of chronic myeloid leukemia
- •received high-dose cytarabine (total cumulative dose of >6g/m sq)in last 6 months
- •interval of <6 months between first onset of last complete remission and current relapse
- •those with primary refractory leukemia who have received more than three previous induction cycles
- •relapsed patients who have received more than three previous treatment regimens
Outcomes
Primary Outcomes
The prorportion of patients achieving a completel response (CR) after the first cycle of treatment in each treatment group
Secondary Outcomes
No secondary outcomes reported
Investigators
Study Sites (19)
Loading locations...
Similar Trials
Completed
Phase 1
Study of the Tolerability, Pharmacokinetics, and Pharmacodynamics of INS50589 Intravenous Infusion in Healthy VolunteersCardiovascular DiseaseNCT00099450Merck Sharp & Dohme LLC48
Active, not recruiting
Phase 1
Fixed Order, Open-Label, Dose-Escalation Study of DMT in HumansMajor Depressive DisorderDepressionNCT04711915Yale University30
Completed
Phase 1
A Phase 1 Dose Escalation Trial of ASG-5ME in Pancreatic or Gastric AdenocarcinomaGastric NeoplasmsPancreatic NeoplasmsNCT01166490Seagen Inc.51
Completed
Phase 1
An Open-label Safety, Tolerability, and Dose-range Finding Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA)Spinal Muscular AtrophyNCT01494701Biogen28
Terminated
Phase 2
An Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics Study of JNJ-17299425 in Participants With Traumatic Brain InjuryTraumatic Brain InjuryNCT01814982Johnson & Johnson Pharmaceutical Research & Development, L.L.C.7